Related Experiment Video
Updated: May 16, 2026
07:29
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Integrated phase II/III clinical trials in oncology: a case study
Meihua Wang1, James J Dignam, Qiang E Zhang
1Department of Statistics, Radiation Therapy Oncology Group, American College of Radiology, Philadelphia, PA, USA. sumswang@yahoo.com
Clinical Trials (London, England)
|November 28, 2012
Summary
Integrated phase II/III trial designs offer benefits like smaller sample sizes and shorter study durations in oncology. However, careful simulation is recommended to weigh potential advantages against disadvantages before implementation.
Area of Science:
- Oncology Clinical Trials
- Biostatistics
- Clinical Trial Design
Background:
- Integrated phase II/III trial designs combine early and late-phase oncology studies.
- Despite documented benefits, their adoption in oncology trials remains limited.
- This study reviews the merits and drawbacks of these designs.
Purpose of the Study:
- To discuss the advantages and disadvantages of integrated phase II/III clinical trial designs in oncology.
- To provide an example of operating characteristics using a Radiation Therapy Oncology Group (RTOG) trial.
Main Methods:
- Review of proposed integrated phase II/III designs.
- Illustration of design use in an RTOG brain tumor trial.
- Examination of endpoint association impact on type I error, power, duration, and sample size.
Main Results:
- Integrated phase II/III designs can yield significant gains under appropriate conditions.
- Benefits include reduced sample size, time, and resource savings.
- Shorter study duration is a key advantage.
Conclusions:
- Integrated phase II/III designs are not universally applicable.
- Potential benefits must be weighed against possible disadvantages.
- Simulations are recommended to evaluate theoretical and practical issues before implementation.
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...